Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Allison Wiesman

Pediatrics Greenfield, IN Medical Doctor

NPI 1710198957 CMS profile 349775

156 W Muskegon Dr, Greenfield, IN 46140

Open in the dashboard

General payments

$3,833

260 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allison Wiesman of Greenfield, IN is reported in the CMS Open Payments database as having received $3,833 across 260 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $456 33
2024 General $874 50
2023 General $653 41
2022 General $619 47
2021 General $551 40
2020 General $273 23
2019 General $406 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allison Wiesman
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Allison Wiesman were reported at $456. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Allison Wiesman Pediatrics median Middle half National median
2019 $406 $86 $31–$183 $163
2020 $273 $49 $22–$110 $114
2021 $551 $68 $27–$158 $132
2022 $619 $77 $30–$173 $149
2023 $653 $88 $33–$190 $160
2024 $874 $94 $34–$206 $164
2025 $456 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $904 47 payments
  2. Tris Pharma Inc $801 64 payments
  3. Corium, Inc. $656 60 payments
  4. Pfizer Inc. $273 20 payments
  5. Ironshore Pharmaceuticals Inc. $216 11 payments
  6. Sanofi Pasteur Inc. $161 8 payments
  7. Merck Sharp & Dohme Corporation $150 9 payments
  8. Collegium Pharmaceutical, Inc. $106 5 payments
  9. Cranial Technologies, Inc $96 6 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $89 6 payments
  11. Other $380 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,805 259 payments
  2. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. Azstarys $656 60 payments
  2. Qelbree Viloxazine Hydrochloride $465 19 payments
  3. QELBREE Psychology $439 28 payments
  4. Dyanavel XR Adhd $305 18 payments
  5. Dyanavel XR Adhd $203 21 payments
  6. JORNAY PM $142 6 payments
  7. GARDASIL 9 $137 8 payments
  8. EUCRISA $136 10 payments
  9. Quillivant $114 12 payments
  10. MENQUADFI $107 5 payments
  11. Other $2,077 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

260 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record